Full text
Earnings transcript
Read the complete earnings call transcript.
LH
Labcorp Holdings Inc.
$273.72
0.98
(0.36%)
| Exchange: | NYSE |
| Market Cap: | 22.691B |
| Shares Outstanding: | 39.6M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Diagnostics & Research | |||||
| CEO: | Adam H. Schechter | |||||
| Full Time Employees: | 60900 | |||||
| Address: |
| |||||
| Website: | https://www.labcorp.com |
Labcorp Holdings, Inc. provides laboratory services to help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 12,161,600 | 13,008,900 | 13,951,700 |
| Gross Profit | 3,364,900 | 3,624,400 | 3,732,500 |
| EBITDA | 1,349,400 | 1,811,300 | 2,012,700 |
| Operating Income | 725,600 | 1,086,700 | 1,516,200 |
| Net Income | 418,000 | 746,000 | 876,500 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 16,725,100 | 18,379,000 | 18,392,700 |
| Total Liabilities | 8,834,600 | 10,312,500 | 9,756,000 |
| Total Stockholders Equity | 7,875,000 | 8,052,200 | 8,619,800 |
| Total Debt | 5,954,200 | 7,272,800 | 6,526,000 |
| Cash and Cash Equivalents | 536,800 | 1,518,700 | 532,299.999 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 1,327,700 | 1,585,800 | 1,640,500 |
| Capital Expenditure | -453,600 | -489,899.999 | -434,500 |
| Free Cash Flow | 874,100 | 1,095,900 | 1,206,000 |
| Net Income | 379,200 | 746,000 | 877,700 |
| Net Change in Cash | 216,199.999 | 981,900 | -986,400 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 15,025,430.543 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 15,403,198.573 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 15,223,225.778 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 2,521,442.274 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 2,584,836.150 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 2,554,634.619 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 1,960,752.423 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 2,025,092.388 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 1,994,440.023 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 2,384,403.496 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 2,444,351.955 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 2,415,791.858 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 23.800 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 24.170 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 23.400 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 5 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 2 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Financial Performance: Labcorp Holdings reported strong financial results in Q3 2025, with revenue and net income growth surpassing expectations, as highlighted in the earnings call transcript. Key metrics such as return on equity (ROE TTM) and net profit margin (TTM) indicate efficient capital utilization and profitability compared to industry benchmarks.
- Operational Efficiency: The company’s free cash flow (TTM) remains solid, supported by consistent operating cash flow as per cash flow statements. This financial stability enables reinvestment in growth initiatives and debt management.
- Strategic Acquisitions: Recent earnings call summaries emphasize Labcorp’s focus on growth through strategic acquisitions, enhancing its market position and service offerings within the healthcare diagnostics sector.
- Technological Advancements: Investment in technology and innovation, as noted in the Q3 2025 earnings call, positions Labcorp as a leader in adopting cutting-edge solutions, potentially driving long-term operational improvements.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates LH intrinsic value between $191.06 – $256.63 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about LH valuation
Is Labcorp Holdings Inc. (LH) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Labcorp Holdings Inc. (LH) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is LH a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether LH trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is LH’s P/E ratio?
You can see LH’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for LH?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is LH a good long-term investment?
Whether LH fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
LH
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
0.36
Trading Metrics:
| Open: | 270.62 | Previous Close: | 272.74 | |
| Day Low: | 270.22 | Day High: | 276.46 | |
| Year Low: | 209.38 | Year High: | 293.72 | |
| Price Avg 50: | 273.84 | Price Avg 200: | 267.77 | |
| Volume: | 467033 | Average Volume: | 648529 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeLH full analysis
Welcome to MARKETSNAP’s SWOT analysis for Labcorp Holdings, also known by its ticker LH. If you’re a long-term investor looking to build wealth through smart stock picks, you’re in the right place. Today, we’re diving deep into Labcorp Holdings, a key player in the healthcare diagnostics and research space. Let’s break down what makes this company tick, analyze its recent performance, and unpack a detailed SWOT to see if it’s a worthy addition to your portfolio. Stick with me as…
